Observational Study
Copyright ©The Author(s) 2025.
World J Diabetes. Feb 15, 2025; 16(2): 98423
Published online Feb 15, 2025. doi: 10.4239/wjd.v16.i2.98423
Table 1 Comparison of the clinical data among the groups
Group
Number of patients (male/female)
Age (years)
BMI (kg/m2)
Smoking (n)
TC (mmol/L)
TG (mmol/L)
HDL-C (mmol/L)
A160 (80/80)60.07 ± 10.4725.1 ± 2.9485.01 ± 1.111.64 ± 0.971.09 ± 0.46
B200 (100/100)61.40 ± 9.9725.0 ± 3.1604.69 ± 0.75b1.27 ± 0.60b1.18 ± 0.27
C60 (30/30)59.99 ± 10.3225.2 ± 3.0144.76 ± 1.12b1.29 ± 0.60b1.24 ± 0.28b
Table 2 Ki-67 expression among the three groups
Group
Number of patients
Negative (%)
Weakly positive (%)
Moderately positive (%)
Strongly positive (%)
Total positive rate (%)
A16021 (13.13)60 (37.50)42 (26.25)37(23.13)139 (86.87)
B20046 (23.00)107 (53.50)b24 (12.00)b23 (11.50)b154 (77.00)a
C6058 (96.67)2 (3.33)b,d0b,d0b,d2 (3.33)b,d
Table 3 Logistic regression analysis of factors influencing the risk of adenocarcinoma in situ and type 2 diabetes mellitus
Independent variables
β
Standard error
Wald
OR (95%CI)
P value
Ki-67−0.1400.0459.6970.870 (0.796–0.950)0.002
FPG0.6540.2347.8101.923 (1.216–3.043)0.005
HbA1c1.4520.69015.03611.563 (2.165-12.016)< 0.01
Insulin−0.1260.0574.8800.882 (0.788–0.986)0.027
HDL-C−3.1511.1517.4950.043 (0.004–0.409)0.006
TC1.1370.5154.8643.116 (1.135–8.556)0.027
TG0.0540.4050.0181.056 (0.477–2.336)0.893
LDL-C0.3770.3810.9781.458 (0.691–3.077)0.323